EyePromise announced that on July 1, 2018, macular pigment optical density (MPOD) measurement by heterochromatic flicker photometry has earned a Category III CPT Code from the American Medical Association. While this code does not receive paid reimbursement, Category III CPT Codes are used for data collection and tracking for products or services involved in planned or ongoing research to help researchers substantiate widespread usage and efficacy.
“MPOD is an important measurement as it allows clinicians another data point to assess a patient’s risk level for developing age related eye disorders such as macular degeneration,” Dennis Gierhart, PhD, Co-Founder, Chairman, and CSO of EyePromise, said in a company news release. “We’re excited to see this assessment gaining traction in the clinical setting.”
The code is effective for dates of service on or after July 1, 2018.